The Filing Desk

Starling Oncology vs Veracyte

Starling Oncology STLN · Veracyte VCYT · Health Care Services

Veracyte reported revenue of $517 million in fiscal 2025, about the same as Starling Oncology's $503 million in fiscal 2025. Starling Oncology's revenue grew 27.8% in its latest year, and Veracyte's grew 16.0%. Starling Oncology had an operating margin of -7.2%, against 11.2% at Veracyte. Free cash flow was −$28 million at Starling Oncology and $127 million at Veracyte.

Side by side

Starling OncologyVeracyte
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$503M$517M
Revenue growth27.8%16.0%
Revenue growth a year, last 5 years21.8%34.5%
Gross margin—70.1%
Operating margin−7.2%11.2%
Net margin−12.1%12.8%
Free cash flow−$28M$127M
Free cash flow margin−5.5%24.5%
Return on capital−75.7%6.1%
Net debt to EBITDA—−4.6x
Dividends and buybacks$0M$0M
Change in diluted share count23.1%3.1%
Last close$3.50$24.33
P/E at the last close—15.8×
Insider trades, last 12 months—sold $19.2 million
Piotroski F-score3 of 86 of 9
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Starling OncologyVeracyte
Operating margin
Percent of revenue
Starling OncologyVeracyte
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Starling OncologyVeracyte

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Starling Oncology and Veracyte pages.